



PATENTS

Attorney Docket No. CENT/008 DIV CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Murray et al.
Application No. : 10/052,879 Confirmation No. : 1807
Filed : October 22, 2001
For : METHODS FOR USE OF MPL LIGANDS WITH
PRIMITIVE HUMAN STEM CELLS
Group Art Unit : 1635
Examiner : Sean McGarry

December 13, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b) and (c)

NOVARTIS AG, a corporation organized and existing under the laws of the Swiss Confederation, having an office and place of business at Lichtstrasse 35, Basel 4078, Switzerland ("NOVARTIS"), represents that it is the assignee of record of the entire right, title and interest, by assignment, of the following:

United States Application 10/052,879 ("the '879 application"), for "METHODS FOR USE OF MPL LIGANDS WITH PRIMITIVE HUMAN STEM CELLS," filed on October 22, 2001, which is a continuation of Application 09/328,188, filed on

June 8, 1999, now U.S. Patent 6,326,205 ("the '205 patent"), which is a division of Application 08/550,167, filed October 30, 1995, now U.S. Patent 6,060,052 ("the '052 patent").

An assignment to NOVARTIS of the entire right, title and interest in and to the subject matter of the '879 application, the '052 and '205 patents was recorded in the United States Patent and Trademark Office on January 24, 2003 at Reel/Frame 013380/0584 (copy attached).

The undersigned, on behalf of NOVARTIS, hereby disclaims the terminal portion of any patent granted on the '879 application which would extend beyond the expiration date of the '052 patent or the '205 patent.

The undersigned, on behalf of NOVARTIS, agrees that any patent so granted on the '879 application shall be enforceable only for and during such period as the legal title to said patent shall be the same as the legal title to the '052 patent and the '205 patent, this agreement to run with any patent granted on the '879 application and to be binding upon the grantee of the patent and its successors and assigns.

The undersigned does not disclaim any terminal portion of any patent granted on the '879 application prior to the full statutory term of the '052 patent or the '205 patent, in the event that the '052 patent or the '205 patent subsequently (a) expires for failure to pay a maintenance fee, (b) is held unenforceable, (c) is found invalid by a court of competent jurisdiction, (d) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), (e) has all claims canceled by a reexamination certificate, or (f) is otherwise

terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

The undersigned hereby states and certifies that:

1. The undersigned is authorized to act on behalf of assignee corporation in connection with said application; and
2. The above-identified assignment document has been reviewed and, to the best of the undersigned's and assignee's knowledge and belief, title to the '879 application, the '052 patent and the '205 patent is in assignee.

Respectfully submitted,




John Prince (Reg. No. 43,019)
Corporate Intellectual Property
Novartis Services, Inc.
400 Technology Square
Room 605-868
Cambridge, MA 02139

Tel.: 617 871 3346

Fax.: 617 871 3392

JANUARY 28, 2003

NOVARTIS
THOMAS HOXIE
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA, BLDG. 430
EAST HANOVER, NJ 07936-1080



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

700023103A

700023103A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/24/2003

REEL/FRAME: 013380/0584
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
SYSTEMIX, INC.

DOC DATE: 01/24/2003

ASSIGNEE:
NOVARTIS AG
LICHSTRASSE 35
BASEL, SWITZERLAND 4058

SERIAL NUMBER: 10052897
PATENT NUMBER:

FILING DATE: 01/16/2002
ISSUE DATE:

SERIAL NUMBER: 08550167
PATENT NUMBER: 6060052

FILING DATE: 10/30/1995
ISSUE DATE: 05/09/2000

SERIAL NUMBER: 09328188
PATENT NUMBER: 6326205

FILING DATE: 06/08/1999
ISSUE DATE: 12/04/2001

JEFFREY OLSEN, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS
